Management of people with intermediate-stage hepatocellular carcinoma
Author:
Affiliation:
1. Sheila Sherlock Liver Centre; Royal Free Hospital and the UCL Institute of Liver and Digestive Health; London UK
2. Division of Surgery and Interventional Science; University College London; London UK
Publisher
Wiley
Subject
Pharmacology (medical)
Reference183 articles.
1. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial;Bruix;Journal of hepatology,2012
2. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona clinic liver cancer (BCLC) stage;Bruix;Journal of Hepatology,2009
3. Sorafenib in advanced hepatocellular carcinoma;Llovet;New England Journal of Medicine,2008
4. Efficacy and safety of combined sequential treatment with RFA and sorafenib in patients with HCC in intermediate stage ineligible for TACE: a prospective randomized open study;Stefano;Journal of Hepatology,2015
5. Efficacy and safety of combined sequential treatment with radiofrequency ablation and sorafenib in patients with hepatocellular carcinoma in intermediate stage ineligible for TACE: a prospective randomized open study;Stefano;Annals of Oncology,2015
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of treatments with radiotherapy alone and radiotherapy plus chemo-immunotherapy in patients with primary liver cancer based on blood biomarkers;Current Medicinal Chemistry;2023-08-22
2. Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma;Cancers;2022-12-05
3. The priority of liver resection compared with transarterial chemoembolization in hepatocellular carcinoma at BCLC B1 stage: A single-center experience;Frontiers in Surgery;2022-11-09
4. Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery;Biomedical Materials;2022-05-13
5. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma;World Journal of Gastrointestinal Surgery;2020-03-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3